X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (669) 669
Book Review (85) 85
Conference Proceeding (40) 40
Publication (24) 24
Book Chapter (9) 9
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (364) 364
humans (347) 347
cardiac & cardiovascular systems (302) 302
male (219) 219
female (218) 218
middle aged (178) 178
abridged index medicus (176) 176
aged (175) 175
treatment outcome (131) 131
risk factors (121) 121
cardiovascular (109) 109
heart attacks (109) 109
mortality (106) 106
atrial fibrillation (100) 100
acute coronary syndromes (93) 93
internal medicine (82) 82
cardiology (81) 81
heart attack (74) 74
myocardial infarction - drug therapy (73) 73
anticoagulants (72) 72
coronary heart disease (71) 71
electrocardiography (71) 71
analysis (69) 69
drug therapy (69) 69
stroke (68) 68
care and treatment (67) 67
peripheral vascular disease (67) 67
warfarin (67) 67
double-blind method (64) 64
acute myocardial-infarction (57) 57
clinical trials (57) 57
risk (55) 55
anticoagulants - therapeutic use (54) 54
cardiac patients (52) 52
fibrinolytic agents - therapeutic use (52) 52
atrial fibrillation - drug therapy (51) 51
thrombolytic therapy (50) 50
myocardial infarction (49) 49
cardiovascular disease (48) 48
cholesterol (48) 48
therapy (48) 48
time factors (48) 48
drug therapy, combination (47) 47
myocardial infarction - mortality (47) 47
coronary angiography (46) 46
myocardial-infarction (46) 46
outcomes (46) 46
prognosis (46) 46
edoxaban (43) 43
follow-up studies (43) 43
patient outcomes (43) 43
platelet aggregation inhibitors - therapeutic use (43) 43
stroke - prevention & control (43) 43
acute coronary syndrome (41) 41
hemorrhage - chemically induced (41) 41
adult (40) 40
unstable angina (40) 40
cardiology and cardiovascular medicine (39) 39
research (39) 39
atrial fibrillation - complications (38) 38
myocardial infarction - therapy (38) 38
risk assessment (37) 37
acute coronary syndrome - drug therapy (36) 36
prevention (36) 36
anticoagulants - administration & dosage (35) 35
dose-response relationship, drug (35) 35
medical research (35) 35
medicine, general & internal (35) 35
metaanalysis (35) 35
anticoagulation (34) 34
cardiovascular diseases (34) 34
medical colleges (34) 34
platelet glycoprotein gpiib-iiia complex - antagonists & inhibitors (34) 34
coronary vessels (33) 33
diabetes (33) 33
medicine & public health (33) 33
cholesterol, ldl - blood (32) 32
health aspects (32) 32
heart failure (32) 32
randomized controlled trials as topic (32) 32
safety (32) 32
management (31) 31
medicine, experimental (31) 31
thrombolysis (31) 31
trial (31) 31
ezetimibe (30) 30
statins (30) 30
transluminal angioplasty (30) 30
angioplasty (29) 29
clinical outcomes (29) 29
dosage and administration (29) 29
warfarin - therapeutic use (29) 29
administration, oral (28) 28
anticoagulants - adverse effects (28) 28
cardiac arrhythmia (28) 28
dabigatran (28) 28
pyridines - therapeutic use (28) 28
acute coronary syndrome - therapy (27) 27
aged, 80 and over (27) 27
myocardial infarction - physiopathology (27) 27
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Circulation, ISSN 0009-7322, 01/2018, Volume 137, Issue 4, pp. 338 - 350
BACKGROUND:The PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events... 
atherosclerosis | amputation | cholesterol, LDL | evolocumab | peripheral arterial disease | PCSK9 protein, human | intermittent claudication | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | LIMB ISCHEMIA | ATORVASTATIN | STATIN THERAPY | AMPUTATION-FREE SURVIVAL | PERIPHERAL VASCULAR DISEASE | POLYVASCULAR DISEASE | PEOPLE | SIMVASTATIN | ASSOCIATION | Dyslipidemias - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Serine Proteinase Inhibitors - therapeutic use | Dyslipidemias - blood | Time Factors | Serine Proteinase Inhibitors - adverse effects | Amputation | Peripheral Arterial Disease - blood | Cholesterol, LDL - blood | Female | Dyslipidemias - diagnosis | Dyslipidemias - drug therapy | Limb Salvage | Down-Regulation | Risk Factors | Treatment Outcome | Biomarkers - blood | Proprotein Convertase 9 - metabolism | Anticholesteremic Agents - adverse effects | Peripheral Arterial Disease - mortality | Peripheral Arterial Disease - therapy | Anticholesteremic Agents - therapeutic use | Peripheral Arterial Disease - diagnosis | Proprotein Convertase 9 - antagonists & inhibitors | Aged | Cholesterol, LDL | Care and treatment | Research | Peripheral vascular diseases | Cardiovascular diseases | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 02/2016, Volume 67, Issue 4, pp. 353 - 361
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 09/2016, Volume 68, Issue 11, pp. 1169 - 1178
Journal Article
Circulation, ISSN 0009-7322, 01/2014, Volume 129, Issue 2, pp. 234 - 243
Journal Article
Circulation, ISSN 0009-7322, 08/2018, Volume 138, Issue 8, pp. 756 - 766
BACKGROUND:The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) recently showed that the PCSK9... 
PCSK9 protein | clinical trial [publication type] | COST-EFFECTIVENESS | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | TICAGRELOR | myocardial infarction | SECONDARY PREVENTION | INFARCTION | THERAPY | LDL | cholesterol | PERIPHERAL VASCULAR DISEASE | human | CARDIOVASCULAR RISK | PROGRESSION | Drug therapy | Coronary heart disease
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 08/2013, Volume 128, Issue 9, pp. 962 - 969
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 8, pp. 787 - 788
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2019, Volume 73, Issue 10, pp. 1132 - 1134
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2005, Volume 352, Issue 16, pp. 1646 - 1654
Journal Article
Heart, ISSN 1355-6037, 03/2014, Volume 100, Issue 5, pp. 396 - 405
Background Antithrombotic therapy reduces stroke, embolism and mortality in patients with atrial fibrillation (AF); however, meta-analyses have focused on... 
CARDIAC & CARDIOVASCULAR SYSTEMS | DABIGATRAN | THERAPY | STROKE PREVENTION | EFFICACY | WARFARIN | SAFETY | RIVAROXABAN | ANTICOAGULANT DRUGS | APIXABAN | ASPIRIN
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2019, Volume 73, Issue 10, pp. 1132 - 1134
Data from the Framingham Heart Study demonstrated that the presence of mitral stenosis (MS) in patients with atrial fibrillation (AF) increases the risk of... 
atrial fibrillation | intracranial hemorrhage | systemic embolism | mitral stenosis | ischemic stroke | STROKE | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | DABIGATRAN | WARFARIN | ORAL ANTICOAGULANTS | RHEUMATIC HEART-DISEASE | Heart | Cardiac arrhythmia | Anticoagulants | Stroke | Fibrillation | Embolisms | Surgery | Mortality | Stenosis | Clinical trials | Cardiovascular disease | Thromboembolism
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 10/2019, Volume 21, Issue 10, pp. 2342 - 2343
Journal Article
Circulation, ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A16771 - A16771
IntroductionRecently medical therapies have shown benefit in reducing major adverse limb events (MALE) including acute limb ischemia (ALI), urgent... 
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 06/2011, Volume 123, Issue 23, pp. 2681 - 2689
Background-The balance between benefit (ischemia protection) and risk (bleeding) is a key consideration in choosing the intensity of antiplatelet therapy for... 
clopidogrel | mortality | prasugrel | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | METAANALYSIS | ELEVATION | PREVENTION | RISK | ACUTE CORONARY SYNDROMES | ASPIRIN | IMPACT | RESIDUALS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | INTERVENTION | Piperazines - administration & dosage | Prasugrel Hydrochloride | Predictive Value of Tests | Myocardial Infarction - mortality | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Hemorrhage - mortality | Male | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Thrombolytic Therapy - methods | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Risk Factors | Proportional Hazards Models | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Hemorrhage - diagnosis | Myocardial Infarction - drug therapy | Aged | Hemorrhage - chemically induced | Thrombolytic Therapy - adverse effects | Aggregation | Usage | Prognosis | Blood platelets | Myocardial ischemia | Diagnosis | Health aspects | Risk factors | Heart attack | Index Medicus | Abridged Index Medicus
Journal Article